美国 · 交易所与实时行情 · Nasdaq

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

来源：Nasdaq · 美国 2 小时前

Key PointsOne of CRISPR Therapeutics’ leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy.

在 Nasdaq 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.nasdaq.com)

推荐阅读

Record Tanker Rates Cripple U.S. Crude Oil Flows to Asia

Warren Buffett’s Value Investing Strategy for Wealth: Patience and Quality

Worldcoin Drops 13% as Institution Moves 19.7M WLD

Introducing new self-learning context enrichment in Knowledge Catalog